first response rate - MARKETS
Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German biotech tastes its first clinical success. The Munich-based company is ... Seeking Alpha: TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Apollo reports five effective sales sequences for higher response rates, emphasizing personalization and timing to boost outreach success.
Understanding the Context
FierceBiotech: ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor interest FierceBiotech: Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients as “impressive,” despite this rate halving at the 12-month mark. The New ... Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months Cure Today: Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma